'Secondary endpoint' presentation slideshows

End points in IBD treatment Mucosal healing Vs Symptom relief

End points in IBD treatment Mucosal healing Vs Symptom relief. Jose Francis Lakeshore Hospital Kochi. Introduction. No cure for IBD No end points available!!. Treatment goals. * Maintenance of remission * Maintenance of QOL. * SYMPTOM RELIEF. Additional goals!!.

586 views • 42 slides

1 Salles GA et al. Proc ASH 2011 ; Abstract 268. 2 Sehn LH et al. Proc ASH 2011;Abstract 269.

457 views • 24 slides

Steven E. Nissen MD

STRADIVARIUS Effect of Rimonabant on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease. Steven E. Nissen MD.

364 views • 23 slides

Aortic Symposium 2010

247 views • 12 slides

Fenofibrate Intervention and Event Lowering in Diabetes

FIELD. Fenofibrate Intervention and Event Lowering in Diabetes. Presented at The American Heart Association Scientific Sessions, November 2005 Presented by Dr. Anthony Keech. FIELD: Background.

122 views • 10 slides

Japanese Approach to colon cancer and the Outcome

Japanese Approach to colon cancer and the Outcome. Kenichi Sugihara. Dep. of Surgical Oncology Tokyo Medical and Dental University. Overall Survival. 1997 ? 2000 in 18 hospitals. 1.0. 84.6%. Colon Ca (n=3061). 0.8. P = 0.0033. Survival rate. 80.6%. 0.6. Rectal Ca (n=1393).

245 views • 9 slides

Treating to New Targets Study

TNT Trial. Treating to New Targets Study. Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa. TNT Trial. 10,003 patients with stable coronary heart disease Age 35-75 years, LDL between 130 and 250 mg/dL, triglyceride ? 600 mg/dL

514 views • 8 slides

Reviewer: Dr Phil Bedard Date posted: June 21, 2007

Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years Authors: Gramont et al. Reviewer: Dr Phil Bedard Date posted: June 21, 2007. Background. MOSAIC trial Primary endpoint = DFS

195 views • 7 slides

Role of - Azilsartan - Azilsartan/ chlorthalidone

Role of - Azilsartan - Azilsartan/ chlorthalidone. Azilsartan. Azilsartan Medoximil (AZL-M) is the prodrug of a potent and selective Angiotensin Receptor blocker (ARB) undergoing development for the treatment of hypertension.

103 views • 7 slides

Cardiac Resynchronization Heart Failure Study

CARE-HF Study. Cardiac Resynchronization Heart Failure Study . Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. John G. Cleland. CARE-HF Study.

353 views • 5 slides

Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

EPHESUS Trial. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Presented at ACC 2003 Late Breaking Clinical Trials N Engl J Med 2003;348:1309-21. EPHESUS Trial. 6,632 patients with acute MI complicated by heart failure and systolic left ventricular dysfunction

965 views • 5 slides